Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
Polymyalgia rheumatica; This is a spontaneous report received from a Consumer or other non HCP, Program ID: . A patient (age and gender not provided) received BNT162b2 (BNT162B2), in 2021 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: POLYMYALGIA RHEUMATICA (medically significant) with onset 2021, 1 week after the suspect product(s) administration, outcome "unknown". The event "polymyalgia rheumatica" required physician office visit. The patient underwent the following laboratory tests and procedures: tested: (2021) Polymyalgia rheumatica. Therapeutic measures were taken as a result of polymyalgia rheumatica. Clinical course: the patient developed severe hip and shoulder 1 week after Covid shot. Later that year the patient was tested, diagnosed and treated by a Rheumatologist for polymyalgia rheumatica. The patient was still taking prednisone as a treatment. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.
Test Date: 2021; Test Name: tested; Result Unstructured Data: Test Result:Polymyalgia rheumatica